US: NY Attorney General launches antitrust investigation into the maker of EpiPen
Mylan Pharmaceuticals, the company that produces EpiPen, is facing scrutiny over its sales contracts with New York school districts.
New York Attorney General Eric Schneiderman announced Tuesday his office has launched an antitrust investigation into Mylan. A preliminary review conducted by Schneiderman’s staff found that the company may have included anti-competitive terms into EpiPen sales contracts with several schools throughout the state.
“No child’s life should be put at risk because a parent, school or health care provider cannot afford a simple, life-saving device because of a drug maker’s anti-competitive practices,” Schneiderman said in a statement.
“If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable. Allergy sufferers have enough concerns to worry about — the availability of life-saving medical treatment should not be one of them. I will bring the full resources of my office to this critical investigation.”
EpiPen is the leading epinephrine autoinjector, which is used to treat someone who experiences a severe allergic reaction. Last month in Auburn, police officers saved a man who had such a reaction after being stung by a bee.
Mylan has drawn criticism recently after it was revealed that the company has raised the price of the EpiPen — the drug is typically sold in a two pack — from $100 in 2007 to $608 today.
In an attempt to address the controversy, Mylan announced that it would sell a generic EpiPen two pack for $300.
Full Content: The Citizen
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh